OR-GUROBI-OPTIMIZATION
14.11.2022 15:01:59 CET | Business Wire | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 10.0. This release provides customers with a boost to its already industry-leading speed, the ability to embed machine learning models directly into Gurobi optimization models, and new tools for model development, monitoring, and advanced diagnosis—so users can solve new types of problems, even faster than before.
Performance Improvements and Advanced Solving Techniques
The Gurobi R&D team continues to push the boundaries of performance—resulting in improvements to existing algorithms and the development of several brand-new techniques. As a result, Gurobi Optimizer 10.0 has achieved the following performance improvements since the release of Gurobi Optimizer 9.5:
Type |
Algorithm |
Overall speed-up |
On >100sec models |
LP |
Concurrent |
10% |
25% |
Primal Simplex |
3% |
10% |
|
Dual Simplex |
3% |
10% |
|
MIP |
MILP |
13% |
24% |
Convex MIQP |
57% |
2.4x* |
|
Convex MIQCP |
28% |
88%* |
|
Non-Convex MIQCP |
51% |
2.6x |
|
*MIQP and MIQCP hard model test sets are smaller than for other problem classes. |
|||
“We’ve achieved a more than 75x speedup on MILP since version 1.1. But more importantly, Gurobi 10.0 can now solve even more models easily, including some models that were, until now, intractable,” explained Dr. Tobias Achterberg, Vice President of Research and Development at Gurobi Optimization.
Gurobi 10.0 also includes the following advances in the underlying algorithmic framework:
- New network simplex algorithm – Greatly speeds up solving LPs with network structure.
- New heuristic for QUBO models, which can arise in quantum optimization – Improves Gurobi's ability to quickly find good feasible solutions for quadratic unconstrained Boolean optimization problems.
- Significant performance gains on MIPs that contain machine learning models – Results in a more than 10x improvement on certain models that contain embedded neural networks with ReLU activation functions.
- New optimization-based bound tightening (OBBT) algorithm – Greatly speeds up solving nonconvex MIQCP models.
- Reorganized concurrent LP solver – Improves performance and reduces memory footprint.
Innovative Data Science Integration
With Gurobi Machine Learning—an open-source Python project to embed trained machine learning models directly into Gurobi—data scientists can more easily tap into the power of mathematical optimization.
Specifically, Gurobi Machine Learning allows users to add a trained machine learning model as a constraint to a Gurobi model (e.g., from scikit-learn, TensorFlow/Keras, or PyTorch). Thus, users can estimate a real-world system by training a machine learning model, and then use this machine learning model as a constraint in Gurobi, in order to optimize controls on that system.
“We’re aiming to connect the world of data science with the world of optimization. With Gurobi, you can take your machine learning ‘black box’ that’s generating your predictions and plug it directly into your optimization model—enabling you to connect your forecasting with optimization,” explained Achterberg.
With this release, we're also making it more convenient to integrate gurobipy model building with pandas objects through a new, dedicated open-source package. (Available on GitHub/PyPI in Q4 2022.)
Enterprise Development and Deployment Experience
To make its solver even more accessible and easy to use, the Gurobi team has integrated new tools for model development, monitoring, and advanced diagnosis:
- Significant enhancements to the matrix-friendly API in gurobipy – All matrix-friendly modeling objects now support multiple dimensions, and dimension handling leans consistently on NumPy, including broadcasting.
- New logistic general constraint – Makes it easy to incorporate a constraint in MIP that models the logistic function.
- NuGet package for .NET – Allows .NET users to download Gurobi directly from the NuGet server.
- Memory limit parameter that allows graceful exit – Users can set a memory limit and still get the best solution and resume the optimization after the limit was hit.
- New Compute Server dashboards – The Gurobi Compute Server now includes two new dashboards, enabling users to monitor metrics over time and drill down to the actual activity to better understand the cluster usage and application behavior.
- Expanded platform support – Gurobi 10.0 includes support for Python 3.11 and Linux on ARM 64-bit.
Gurobi introduced its Web License Service (WLS) for Docker and Kubernetes container environments last year, with the release of Gurobi 9.5. With Gurobi 10.0, the team has expanded WLS to support nearly all types of containerized environments. Moreover, customers can now also obtain WLS licenses that allow them to run Gurobi in virtually all deployment scenarios, including containerized environments, virtual machines, and bare-metal machines, across Linux, macOS, and Windows.
“Our customers love our WLS and the flexibility it provides. And now they can dynamically deploy Gurobi software in even more environments,” explained Duke Perrucci, Gurobi’s Chief Operating Officer.
Additionally, starting with Gurobi 10.0, major product releases—and their subsequent minor and technical product releases—will be supported for a term of three years from the initial major product release date. For example, Gurobi version 10.0.0 (released in November 2022) and minor releases between 10.0 and 11.0 will be supported until November 2025.
“This helps create predictability for our customers, so they know exactly how long a version will be supported,” explained Dr. Sonja Mars, Director of Optimization Support at Gurobi Optimization. “We aim to deliver expert technical guidance and support for our customers—and this policy helps eliminate the guesswork. We want our customers to get the help they need, when they need it.”
Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization added, “We have the absolute best minds in optimization here at Gurobi. Across every department, you’ll find people who aren’t just smart—they’re also deeply committed to our customers and to providing the best possible experience. I’m proud to be a part of this team.”
To learn more about Gurobi 10.0, please visit gurobi.com/whats-new-gurobi-10-0/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
